K R Rai
Affiliation: Long Island Jewish Medical Center
- Interferon in the treatment of hairy-cell leukemiaShahid Ahmed
Division of Hematology Oncology, Long Island Jewish Medical Center, 270 05, 76th Ave, New Hyde Park, NY 11040, USA
Best Pract Res Clin Haematol 16:69-81. 2003..In this chapter, we discuss the efficacy of interferon and its response duration, toxicity and possible mechanism of action in patients with hairy-cell leukemia...
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyMichael J Keating
M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 99:3554-61. 2002..Alemtuzumab induced significant responses in these patients with clinical benefit in the majority and with acceptable toxicity in a high-risk group...
- Clinical staging and prognostic markers in chronic lymphocytic leukemiaKanti R Rai
Long Island Jewish Medical Center, Division of Hematology Oncology, 270 05 76th Avenue, New Hyde Park, NY 11040, USA
Hematol Oncol Clin North Am 18:795-805, vii. 2004..In this article we provide a brief review of the two staging systems in chronic lymphocytic leukemia, and we discuss the more recently identified, new prognostic markers that are of interest to clinicians and researchers in this field...
- Chronic lymphocytic leukemia: current and emerging treatment approachesNeil E Kay
Mayo Clinic College of Medicine, Rochester, Minn, USA
Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006..Novel agents with unique, nonoverlapping mechanisms of action (eg, oblimersen sodium, lenalidomide, HuMax-CD20, GX15-070), and other treatments are under investigation in an attempt to further improve outcomes...
- Introduction: Chronic lymphocytic leukemia in perspectiveKanti R Rai
Division of Hematology Oncology, Long Island Jewish Med Center, New Hyde Park, NY 11040, USA
Best Pract Res Clin Haematol 20:363-5. 2007....
- Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapyKanti R Rai
Division of Hematology-Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
Exp Hematol 35:134-6. 2007
- Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaK R Rai
Cancer and Leukemia Group B, Chicago, USA
N Engl J Med 343:1750-7. 2000..We compared the efficacy of fludarabine with that of chlorambucil in the primary treatment of chronic lymphocytic leukemia...
- Future prospects for alemtuzumab (MabCampath)Kanti Rai
Long Island Jewish Medical Center New Hyde Park, NY 11042, USA
Med Oncol 19:S57-63. 2002....
- Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemiaKanti R Rai
Division of Hematology Oncology, Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
Semin Oncol 33:S15-22. 2006..A number of clinical trials are under way assessing the role of alemtuzumab in these settings...
- Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabineK R Rai
Long Island Jewish Medical Center, New Hyde Park, NY 11040, USA
J Clin Oncol 20:3891-7. 2002....
- Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-upM A Hoffman
Department of Medicine, Long Island Jewish Medical Center Campus of the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA
J Clin Oncol 15:1138-42. 1997..To analyze initial and long-term outcomes after treatment of patients with active hairy-cell leukemia (HCL) with a single cycle of cladribine (2-CdA)...
- The role of monoclonal antibodies in stem cell transplantationTarun Wasil
Long Island Jewish Medical Center, Division of Hematology-Oncology, New Hyde Park, NY 11040, USA
Semin Oncol 31:83-9. 2004..This review focuses on the currently available data for in vitro and in vivo purging with these antibodies as well as their role in modulating graft-versus-host disease (GVHD)...
- Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemiaN Gupta
Division of Hematology/Oncology, Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA
Leukemia 16:2092-5. 2002..Retreatment with RCD was also effective in achieving a response on relapse of AIHA. Our results indicate that a rituximab-based combination regimen (RCD) is highly effective in treating steroid refractory AIHA of CLL...
- Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemiaLiguang Chen
Division of Hematology Oncology, Department of Medicine, University of California, San Diego for the CLL Research Consortium, San Diego, CA, USA
Blood 100:4609-14. 2002....
- Campath-1H for chronic lymphocytic leukemiaKanti R Rai
Clin Lymphoma 3:73-4. 2002
- Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup studyRobert E Martell
Geriatrics Research, Education and Clinical Center, Veterans Affairs Medical Center and Hematology/Oncology Division, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Cancer Chemother Pharmacol 50:37-45. 2002..0001). CONCLUSIONS: Patient age was not an independent risk factor for fludarabine-related toxicity, but CrCl(est) was associated with time to toxicity...
- Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemiaSusan O'Brien
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 25:1114-20. 2007..We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL...
- Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemiaSusan M O'Brien
M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030 7305, USA
J Clin Oncol 23:7697-702. 2005..To determine the maximum-tolerated dose (MTD), efficacy, safety, and pharmacokinetics of oblimersen sodium in patients with advanced chronic lymphocytic leukemia (CLL)...
- CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cellsRajendra N Damle
Laboratory of Experimental Immunology, The Feinstein Institute for Medical Research, North Shore Long Island Jewish LIJ Health System, 350 Community Drive, Manhasset, NY 11030, USA
Blood 110:3352-9. 2007..These findings may help explain why high percentages of CD38(+) cells within clones are associated with poor clinical outcome...
- Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selectionEmanuela M Ghia
Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA
Blood 111:5101-8. 2008....
- High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) stChristian Langer
Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Blood 111:5371-9. 2008..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaLaura Z Rassenti
The Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA
Blood 112:1923-30. 2008....
- The natural history of CLL and new prognostic markersKanti R Rai
Clin Adv Hematol Oncol 6:4-5; quiz 10-2. 2008
- Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation statusDavorka Messmer
The Laboratory of Experimental Immunology, Institute for Medical Research, North Shore LIJ Health System, Manhasset, New York, USA
Mol Med 10:96-103. 2004..Our data show that DCs generated from the B-CLL subgroup with unmutated Ig V genes are functionally normal. These results are very promising for the use of DCs from patients with poor prognosis for immunotherapy...
- Malignant pleural effusions in lymphoproliferative disordersShahid Ahmed
Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, SK, Canada
Leuk Lymphoma 46:1039-44. 2005..Many clinical and cytochemical markers have discriminatory values in identifying malignant effusion. A high pleural fluid to serum LDH level correlates with malignant pleural involvement and hospital mortality...
- Chronic lymphocytic leukemiaNicholas Chiorazzi
Institute for Medical Research, North Shore-LIJ Health System, Manhasset, NY 11030, USA
N Engl J Med 352:804-15. 2005
- B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytesRajendra N Damle
North Shore-Long Island Jewish Research Institute, Manhasset, NY 11030, USA
Blood 99:4087-93. 2002....
- Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011Vicki A Morrison
Section of Hematology Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
J Clin Oncol 20:3878-84. 2002..A series of patients enrolled onto an intergroup CLL trial were examined for this complication...
- Determining the clinical course and outcome in chronic lymphocytic leukemiaKanti R Rai
N Engl J Med 348:1797-9. 2003
- Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the cloneEmilia Albesiano
North Shore Long Island Jewish Research Institute, 350 Community Dr, Manhasset, NY 11030, USA
Blood 102:3333-9. 2003..These data suggest that AID-mediated DNA alterations may occur in a variably sized, minor subset of B-CLL cells at any given time...
- Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutationsRajendra N Damle
North Shore-Long Island Jewish Research Institute, 350 Community Dr, Manhasset, NY 11030, USA
Blood 103:375-82. 2004..In addition, they reinforce the concept that B-CLL is not simply an accumulative disease of slowly dividing B lymphocytes but possibly one of B cells with extensive proliferative histories...
- Transforming growth factor-beta (TGF-beta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-beta receptorWilliam P Schiemann
Department of Pediatrics, Program in Cell Biology, National Jewish Medical and Research Center, Goodman Building, K1011, 1400 Jackson Street, Denver, CO 80206, USA
Cancer Detect Prev 28:57-64. 2004..Our results demonstrate that TGF-beta-resistant B-CLL is linked to signal sequence mutations within the TbetaR-I gene, and may eventually be employed as a prognostic indicator in B-CLL...
- Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemiaFabio Ghiotto
Department of Medicine, North Shore University Hospital and New York University School of Medicine, Manhasset, New York, USA
J Clin Invest 113:1008-16. 2004....
- Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare diseaseShahid Ahmed
Saskatoon Cancer Center, University of Saskatchewan Campus, 20 Campus Drive, Saskatoon, SK, Canada S7N4 H4
Eur J Cancer 40:1320-6. 2004..It appears that BALT lymphoma tends to be localised to lung at the time of diagnosis, responds well to local or systemic therapy, and has a favourable prognosis...
- Exciting new developments in chronic lymphocytic leukemia: an introduction and an editorialKanti R Rai
Semin Hematol 41:189-90. 2004
- ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaLaura Z Rassenti
Chronic Lymphocytic Leukemia Research Consortium, University of California, San Diego, La Jolla 92093, USA
N Engl J Med 351:893-901. 2004..001). CONCLUSIONS: Although the presence of an unmutated IgV(H) gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL...
- In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cellsBradley T Messmer
Institute for Medical Research, North Shore-LIJ Research Institute, Manhasset, New York 11030, USA
J Clin Invest 115:755-64. 2005..A correlation between birth rates and disease activity and progression appears to exist, which may help identify patients at risk for worsening disease in advance of clinical deterioration...
- Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18)Brian A McCarthy
Laboratory of Experimental Immunology, The Feinstein Institute for Medical Research, Manhasset, New York 11030, USA
Mol Med 14:618-27. 2008..It is not clear if this surface membrane expression is a passive consequence of the apoptotic process or an active attempt by the B cell to abort cell death by stabilizing the plasma membrane...